

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



YUNKANG GROUP LIMITED

云康集团有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 2325)

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR AND CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

This announcement is made by Yunkang Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”) under Rule 13.51(2) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR

The board (the “**Board**”) of directors (the “**Directors**”) is pleased to announce that, with effect from April 10, 2025, Dr. Dong Min (董敏) (“**Dr. Dong**”) has been appointed as an independent non-executive Director of the Company.

PARTICULARS OF DR. DONG

The biographical details of Dr. Dong are as follows:

Dr. Dong, aged 56, is the founder and the current chief executive officer of Bo'an Shining Biotechnology (Shanghai) Co., Ltd. (博安世寧生物技術(上海)有限公司). Dr. Dong has been appointed as an independent non-executive Director with effect from April 10, 2025.

Dr. Dong has rich experience in technological research and product development in the field of biomedicine. From August 2006 to February 2011, she worked at Novartis International AG as a senior scientist in its preclinical drug safety department. From March 2011 to October 2015, she held the position of director of global clinical development in the oncology translational medicine department of Novartis (China Shanghai) Biomedical Research Co., Ltd. (諾華(中國上海)生物醫學研究有限公司). From November 2015 to December 2016, she served as the chief scientist of the Group. From February 2017 to July 2018, she served as the senior vice president responsible for clinical development and regulatory affairs at EOC Pharma Co., Ltd. (億騰景昂藥業股份有限公司). From July 2018 to July 2021, she was the executive vice president responsible for global clinical development and regulatory affairs and the deputy general manager for Greater China at Clover Biopharmaceuticals Co., Ltd. (三葉草生物製藥有限公司). Between August 2021 and January 2023, she founded and served as the chief executive officer of SQZ Biotech (Shanghai) Co., Ltd. (斯摩夫生物科技(上海)有限公司).

In July 1991, Dr. Dong obtained her bachelor's degree from Beijing Medical University (北京醫科大學) (currently known as Peking University Health Science Center (北京大學醫學部)). In July 1999, Dr. Dong obtained her master's degree from Tsinghua University (清華大學). In September 2004, she obtained her Ph.D. degree from Massachusetts Institute of Technology (麻省理工學院) in the United States.

Dr. Dong has entered into a letter of appointment with the Company for a term of three years commencing from the date of her appointment as an independent non-executive Director, which is renewable automatically or terminated by either party by giving not less than three months' written notice, and shall be subject to re-election as and when required under the articles of association of the Company (the "**Articles**") and the Listing Rules. Pursuant to her letter of appointment, Dr. Dong will be entitled to an annual emolument of HK\$250,000. The emoluments of Dr. Dong were recommended by the remuneration committee of the Company and approved by the Board with reference to her background, experience, qualifications, duties and responsibilities with the Company, the Company's remuneration policy as well as the prevailing market conditions. Dr. Dong will hold office until the next following annual general meeting of the Company and shall then be eligible for re-election in accordance with the Articles.

As of the date of this announcement, Dr. Dong does not have any interest in or is deemed to be interested in any shares or underlying shares of the Company or its associated corporations within the meaning of Part XV of the Securities and Futures Ordinance.

As of the date of this announcement and save as disclosed above, Dr. Dong (i) does not hold any other directorship in other public companies the securities of which are listed on any securities market in Hong Kong or overseas in the last three years preceding the date of this announcement or any other major appointments and professional qualifications; (ii) does not hold any other positions in the Company and other members of the Group; and (iii) does not have any other relationship with any other Directors, senior management or substantial or controlling shareholders of the Company. Dr. Dong has also confirmed (a) her independence as regards to each of the factors contained in Rule 3.13(1) to (8) of the Listing Rules; (b) that save as disclosed in this announcement, she has no past or present financial or other interest in the business of the Company or its subsidiaries nor any connection with any core connected persons (has the meaning as defined under the Listing Rules) of the Company; and (c) that there are no other factors that may affect her independence at the time of her appointment.

Save as disclosed in this announcement, Dr. Dong has confirmed that there is no other information which requires to be disclosed pursuant to Rule 13.51(2)(h) to (v) of the Listing Rules nor is there any other matter regarding her appointment that needs to be brought to the attention of the shareholders of Company and/or the Stock Exchange.

The Board would like to take this opportunity to welcome Dr. Dong in joining the Board.

CHANGE IN COMPOSITION OF NOMINATION COMMITTEE

The Board hereby announces that with effect from April 10, 2025, (i) Mr. Yu Shiyong, an independent non-executive Director, has ceased to be a member of the nomination committee of the Company (the “**Nomination Committee**”); and (ii) Dr. Dong, an independent non-executive Director, has been appointed as a member of the Nomination Committee. Following the above changes, the Nomination Committee comprises Mr. Zhang Yong (chairman), Mr. Xie Shaohua and Dr. Dong, and has one Director of a different gender.

The above changes were implemented in response to the amended Corporate Governance Code and the Listing Rules which will come into effect on July 1, 2025. Good corporate governance plays a significant role in the overall performance of the Company and the Board believes that the implementation of such changes could strengthen the effectiveness and diversity of the Board and further enhance good corporate governance practice of the Company as a whole.

By order of the Board
Yunkang Group Limited
Zhang Yong
Chairman

Guangzhou, the PRC
April 10, 2025

As of the date of this announcement, the Board comprises Mr. Zhang Yong as chairman and executive Director; Ms. Huang Luo, Dr. Wang Pinghui and Dr. Wang Ruihua as non-executive Directors; and Mr. Yu Shiyong, Mr. Xie Shaohua and Dr. Dong Min as independent non-executive Directors.